What's my background?
Having graduated with a Bachelor's of Science in Biology from MIT, I've had an interest in both life sciences and business since 2010. In my senior year, I worked on a health economics project at the Sloan School of Management (with Professor Joseph Doyle) that evaluated the relationship between costs and clinical outcomes for non-profit vs for-profit hospitals. I've also worked as a consultant for a boutique life sciences consulting firm located in Cambridge (CBT Advisors) and have been exposed to a variety of projects in the biotech, pharma, health IT, and venture capital industries. Lastly, I have served as a volunteer consultant for a HIV education non-profit located in Palo Alto (TeachAIDS) since 2011. I currently work full-time as a researcher and manager at the Cardiovascular Thrombosis Laboratory at Massachusetts General Hospital and continue to consult part-time. In the next few years, I plan to pursue a joint MD/MBA.
Why biotech?
With 20+ biotech IPOs in the first half of 2013, the biotech industry has definitely come back to life. After years of minimal activity since the financial crisis of 2008, biotechs have rebounded with $1.4 B in investments and double the number of IPOs (See FierceBiotech's Special Report on 2013 Biotech IPOs for a great summary of IPOs in 2013)1. With so many new technologies and eager investors, there are also no signs of slowing down; dozens of biotechs are lined up in the IPO queue. In fact, since 2009 the biotech sector (i.e iShares Nasdaq Biotechnology- IBB) has actually outperformed the S&P 500 3 to 1.2
My primary interests in writing this blog are to:
1. Identify highly innovative, disruptive companies and perform due diligence
2. Highlight new trends and developments in the industry
3. Provide commentary and opinions on health care policy and laws
For a sample of my previous work, please see pages 20-116 of "Investing in translational research to produce clinical, commercial and financial outcomes: current and future mechanisms," a white paper for the California Institute of Regenerative Medicine. Note: I was the lead analyst for the project and drafted 80+ pages of the white paper.
Sources:
1. http://www.fiercebiotech.com/special-reports/2013-biotech-ipos
2. http://www.eagledailyinvestor.com/2013/07/30/the-red-hot-sector-beating-the-sp-500-by-three-to-one
Having graduated with a Bachelor's of Science in Biology from MIT, I've had an interest in both life sciences and business since 2010. In my senior year, I worked on a health economics project at the Sloan School of Management (with Professor Joseph Doyle) that evaluated the relationship between costs and clinical outcomes for non-profit vs for-profit hospitals. I've also worked as a consultant for a boutique life sciences consulting firm located in Cambridge (CBT Advisors) and have been exposed to a variety of projects in the biotech, pharma, health IT, and venture capital industries. Lastly, I have served as a volunteer consultant for a HIV education non-profit located in Palo Alto (TeachAIDS) since 2011. I currently work full-time as a researcher and manager at the Cardiovascular Thrombosis Laboratory at Massachusetts General Hospital and continue to consult part-time. In the next few years, I plan to pursue a joint MD/MBA.
Why biotech?
With 20+ biotech IPOs in the first half of 2013, the biotech industry has definitely come back to life. After years of minimal activity since the financial crisis of 2008, biotechs have rebounded with $1.4 B in investments and double the number of IPOs (See FierceBiotech's Special Report on 2013 Biotech IPOs for a great summary of IPOs in 2013)1. With so many new technologies and eager investors, there are also no signs of slowing down; dozens of biotechs are lined up in the IPO queue. In fact, since 2009 the biotech sector (i.e iShares Nasdaq Biotechnology- IBB) has actually outperformed the S&P 500 3 to 1.2
My primary interests in writing this blog are to:
1. Identify highly innovative, disruptive companies and perform due diligence
2. Highlight new trends and developments in the industry
3. Provide commentary and opinions on health care policy and laws
For a sample of my previous work, please see pages 20-116 of "Investing in translational research to produce clinical, commercial and financial outcomes: current and future mechanisms," a white paper for the California Institute of Regenerative Medicine. Note: I was the lead analyst for the project and drafted 80+ pages of the white paper.
Sources:
1. http://www.fiercebiotech.com/special-reports/2013-biotech-ipos
2. http://www.eagledailyinvestor.com/2013/07/30/the-red-hot-sector-beating-the-sp-500-by-three-to-one
